Risk for anemia in pediatric chronic kidney disease patients: A report of NAPRTCS

Meredith Atkinson, Karen Martz, Bradley A. Warady, Alicia M Neu

Research output: Contribution to journalArticle

Abstract

Previous studies in children with chronic kidney disease (CKD) have identified low hemoglobin as a risk factor for poor outcomes. A retrospective review of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) CKD registry was performed to identify the prevalence of and risk factors for anemia among children with stage 3 CKD, including both patients with low hemoglobin and those whose hemoglobin normalized with an erythropoiesis-stimulating agent (ESA). At enrollment, 2,792 patients had stage 3 CKD. Mean age was 9.5 (±0.11) years, 62.1% were male, 61.3% were white, and 43.7% had structural/urologic disease. Among 1,640 of those patients with 12 month follow-up data available for multivariate analysis, 73% met the criteria for anemia. Multivariate logistic regression analysis identifying risk factors for anemia at the 12-month follow-up revealed that, after controlling for estimated glomerular filtration rate, age >2 years, male sex, earlier era of study entry, and prescription of anti-hypertensive medications are associated with an increased risk for anemia at 12 months. In addition, multivariate Cox proportional hazards regression analysis revealed that when patients with ESA-corrected hemoglobin are included in the definition, anemia is not associated with increased risk of progression to end stage renal disease (dialysis initiation or transplantation).

Original languageEnglish (US)
Pages (from-to)1699-1706
Number of pages8
JournalPediatric Nephrology
Volume25
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Chronic Renal Insufficiency
Anemia
Pediatrics
Kidney
Hemoglobins
Hematinics
Regression Analysis
Urologic Diseases
Glomerular Filtration Rate
Antihypertensive Agents
Chronic Kidney Failure
Prescriptions
Registries
Renal Dialysis
Multivariate Analysis
Transplantation
Logistic Models

Keywords

  • Anti-hypertensives
  • CKD stage
  • Erythropoietin stimulating agent
  • Progression
  • Risk factors

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Risk for anemia in pediatric chronic kidney disease patients : A report of NAPRTCS. / Atkinson, Meredith; Martz, Karen; Warady, Bradley A.; Neu, Alicia M.

In: Pediatric Nephrology, Vol. 25, No. 9, 09.2010, p. 1699-1706.

Research output: Contribution to journalArticle

@article{c8cfccfd877f448298156a6689e86f5d,
title = "Risk for anemia in pediatric chronic kidney disease patients: A report of NAPRTCS",
abstract = "Previous studies in children with chronic kidney disease (CKD) have identified low hemoglobin as a risk factor for poor outcomes. A retrospective review of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) CKD registry was performed to identify the prevalence of and risk factors for anemia among children with stage 3 CKD, including both patients with low hemoglobin and those whose hemoglobin normalized with an erythropoiesis-stimulating agent (ESA). At enrollment, 2,792 patients had stage 3 CKD. Mean age was 9.5 (±0.11) years, 62.1{\%} were male, 61.3{\%} were white, and 43.7{\%} had structural/urologic disease. Among 1,640 of those patients with 12 month follow-up data available for multivariate analysis, 73{\%} met the criteria for anemia. Multivariate logistic regression analysis identifying risk factors for anemia at the 12-month follow-up revealed that, after controlling for estimated glomerular filtration rate, age >2 years, male sex, earlier era of study entry, and prescription of anti-hypertensive medications are associated with an increased risk for anemia at 12 months. In addition, multivariate Cox proportional hazards regression analysis revealed that when patients with ESA-corrected hemoglobin are included in the definition, anemia is not associated with increased risk of progression to end stage renal disease (dialysis initiation or transplantation).",
keywords = "Anti-hypertensives, CKD stage, Erythropoietin stimulating agent, Progression, Risk factors",
author = "Meredith Atkinson and Karen Martz and Warady, {Bradley A.} and Neu, {Alicia M}",
year = "2010",
month = "9",
doi = "10.1007/s00467-010-1538-6",
language = "English (US)",
volume = "25",
pages = "1699--1706",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Risk for anemia in pediatric chronic kidney disease patients

T2 - A report of NAPRTCS

AU - Atkinson, Meredith

AU - Martz, Karen

AU - Warady, Bradley A.

AU - Neu, Alicia M

PY - 2010/9

Y1 - 2010/9

N2 - Previous studies in children with chronic kidney disease (CKD) have identified low hemoglobin as a risk factor for poor outcomes. A retrospective review of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) CKD registry was performed to identify the prevalence of and risk factors for anemia among children with stage 3 CKD, including both patients with low hemoglobin and those whose hemoglobin normalized with an erythropoiesis-stimulating agent (ESA). At enrollment, 2,792 patients had stage 3 CKD. Mean age was 9.5 (±0.11) years, 62.1% were male, 61.3% were white, and 43.7% had structural/urologic disease. Among 1,640 of those patients with 12 month follow-up data available for multivariate analysis, 73% met the criteria for anemia. Multivariate logistic regression analysis identifying risk factors for anemia at the 12-month follow-up revealed that, after controlling for estimated glomerular filtration rate, age >2 years, male sex, earlier era of study entry, and prescription of anti-hypertensive medications are associated with an increased risk for anemia at 12 months. In addition, multivariate Cox proportional hazards regression analysis revealed that when patients with ESA-corrected hemoglobin are included in the definition, anemia is not associated with increased risk of progression to end stage renal disease (dialysis initiation or transplantation).

AB - Previous studies in children with chronic kidney disease (CKD) have identified low hemoglobin as a risk factor for poor outcomes. A retrospective review of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) CKD registry was performed to identify the prevalence of and risk factors for anemia among children with stage 3 CKD, including both patients with low hemoglobin and those whose hemoglobin normalized with an erythropoiesis-stimulating agent (ESA). At enrollment, 2,792 patients had stage 3 CKD. Mean age was 9.5 (±0.11) years, 62.1% were male, 61.3% were white, and 43.7% had structural/urologic disease. Among 1,640 of those patients with 12 month follow-up data available for multivariate analysis, 73% met the criteria for anemia. Multivariate logistic regression analysis identifying risk factors for anemia at the 12-month follow-up revealed that, after controlling for estimated glomerular filtration rate, age >2 years, male sex, earlier era of study entry, and prescription of anti-hypertensive medications are associated with an increased risk for anemia at 12 months. In addition, multivariate Cox proportional hazards regression analysis revealed that when patients with ESA-corrected hemoglobin are included in the definition, anemia is not associated with increased risk of progression to end stage renal disease (dialysis initiation or transplantation).

KW - Anti-hypertensives

KW - CKD stage

KW - Erythropoietin stimulating agent

KW - Progression

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=77955013503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955013503&partnerID=8YFLogxK

U2 - 10.1007/s00467-010-1538-6

DO - 10.1007/s00467-010-1538-6

M3 - Article

C2 - 20464428

AN - SCOPUS:77955013503

VL - 25

SP - 1699

EP - 1706

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 9

ER -